TriangleNCT04035486 · OUTCOME
Landmark Overall Survival (LOS) at 1, 2, and 3 Years (Randomized Component)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percent of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to approximately 33 months after the first patient is randomized (maximum follow up of 34.1 months)
What was measured
Landmark Overall Survival at 1, 2, and 3 years looks at the percent of patients alive at 1, 2 and 3 year time points. Overall survival at 36 months not included to data cut off prior to 36-month timepoint. Overall survival percentage calculated using the Kaplan-Meier method.
Analysis population: Full Analysis Set, includes all randomized participants.
Groups in this outcome
Randomized: AZD9291 + Chemo
Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W
Randomized: AZD9291
Osimertinib (AZD9291) 80mg QD.
| Group | Source count |
|---|---|
| Randomized: AZD9291 + Chemo | 279 |
| Randomized: AZD9291 | 278 |
Reported measurements
Overall survival at 12 months (%)
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Randomized: AZD9291 + Chemo | 88.8 | Not reported | 84.4 | 92.0 | Not reported |
| Randomized: AZD9291 | 92.0 | Not reported | 88.1 | 94.7 | Not reported |
Overall survival at 24 months (%)
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Randomized: AZD9291 + Chemo | 78.9 | Not reported | 73.4 | 83.4 | Not reported |
| Randomized: AZD9291 | 73.0 | Not reported | 66.9 | 78.1 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 84.4
- upper Limit
- 92.0
- value
- 88.8
- group Id
- OG001
- lower Limit
- 88.1
- upper Limit
- 94.7
- value
- 92.0
- title
- Overall survival at 12 months (%)
- categories
- measurements
- group Id
- OG000
- lower Limit
- 73.4
- upper Limit
- 83.4
- value
- 78.9
- group Id
- OG001
- lower Limit
- 66.9
- upper Limit
- 78.1
- value
- 73.0
- title
- Overall survival at 24 months (%)
- denoms
- counts
- group Id
- OG000
- value
- 279
- group Id
- OG001
- value
- 278
- units
- Participants
- description
- Landmark Overall Survival at 1, 2, and 3 years looks at the percent of patients alive at 1, 2 and 3 year time points. Overall survival at 36 months not included to data cut off prior to 36-month timepoint. Overall survival percentage calculated using the Kaplan-Meier method.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W
- id
- OG000
- title
- Randomized: AZD9291 + Chemo
- description
- Osimertinib (AZD9291) 80mg QD.
- id
- OG001
- title
- Randomized: AZD9291
- param Type
- NUMBER
- population Description
- Full Analysis Set, includes all randomized participants.
- reporting Status
- POSTED
- time Frame
- Up to approximately 33 months after the first patient is randomized (maximum follow up of 34.1 months)
- title
- Landmark Overall Survival (LOS) at 1, 2, and 3 Years (Randomized Component)
- type
- SECONDARY
- unit Of Measure
- percent of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice